Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 16:55:00 11/07/2025 BST			5-day change	1st Jan Change
83.03 ^EUR	-1.34%		-0.31%	-11.43%

07-11	SANOFI : UBS reiterates its Buy rating	ZD
07-10	Delaware Supreme Court sides with Zantac drugmakers over cancer evidence	RE

Sector Update: Health Care Stocks Advance Late Afternoon

Published on 30/05/2025 at 21:00

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Sanofi

SANOFI : UBS reiterates its Buy rating	07-11	ZD
Delaware Supreme Court sides with Zantac drugmakers over cancer evidence	07-10	RE
Delaware Supreme Court sides with Zantac drugmakers over evidence	07-10	RE
Nurix Therapeutics Fiscal Q2 Loss Narrows, Revenue More Than Triples; Shares Surge Premarket	07-10	MT
SANOFI : UBS maintains a Buy rating	07-08	ZD
SANOFI : Goldman Sachs reiterates its Neutral rating	07-03	ZD
Berenberg Keeps Sanofi at Buy on Expanding Pipeline Optionality	07-03	MT
SANOFI : Gets a Buy rating from Berenberg	07-03	ZD
AlphaValue/Baader Europe Cuts Sanofi Price Target Amid Pipeline Setbacks, Leadership Concerns	07-02	MT
SANOFI : Barclays keeps its Buy rating	07-02	ZD
SANOFI : JP Morgan remains Neutral	07-02	ZD
SANOFI : Pipeline disappointments may push out the CEO	07-01
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	07-01	MT
Adagene ADRs Rise Following Sanofi Investment	07-01	DJ
Adagene to Receive up to $25 Million Investment From Sanofi; Shares up Pre-Bell	07-01	MT
SANOFI : UBS reaffirms its Buy rating	07-01	ZD
Euroapi: sells Haverhill site in UK	07-01	CF
Esteve Pharmaceuticals, S.A. agreed to acquire Caprelsa® rights in more than 50 countries from Sanofi.	06-30	CI
Sanofi Advances Rare Neurological Disorder Treatment with Orphan Drug Status in Japan	06-30	MT
Sanofi Announces Riliprubart Granted Orphan Drug Designation in Japan for Chronic Inflammative Demyelinating Polyneuropathy	06-30	CI
Sanofi: riliprubart designated orphan drug in Japan	06-30	CF
Sanofi's Riliprubart Secures Orphan Drug Designation in Japan	06-30	MT
Kennedy's US vaccine panel backs preservative-free shot despite safety evidence	06-26	RE
Pfizer's bleeding disorder therapy succeeds in trial with patients with certain antibodies	06-26	RE
US CDC vaccine panel postpones vote on RSV therapies	06-25	RE

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2024, the group had 52 production sites worldwide. In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation. Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).

Employees

82,878

Sector

Pharmaceuticals

Calendar

07-31 - Q2 2025 Earnings Release

More about the company